Novo Nordisk shares dive after heart medicine fails trial

Novo Nordisk's experimental heart medicine ziltivekimab failed a clinical trial, per CNBC. The drug did not achieve statistically significant improvements in major cardiovascular events. The disappointment drove the company's stock down nine percent.

Listen to this story

Hear this and more stories in a personalized audio briefing.

Open The Chonkerton